kymera - Search News

News

Kymera, Gilead Sciences and breast cancer

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Reuters on MSN · 4d

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal,

Fierce Biotech · 4d

Kymera suffers Sanofi setback but secures $750M Gilead deal

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 million deal with Gilead Sciences.

PMLive3d

Gilead Sciences and Kymera enter oncology partnership worth up to $750m

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

PharmExec4d

Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Nasdaq3d

Kymera Therapeutics Announces $250.8 Million Public Offering of Common Stock and Pre-Funded Warrants - Nasdaq

Potential Positives. Kymera Therapeutics has successfully priced a public offering of $250.8 million, providing significant capital for further development and expansion of its pipeline.

Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results